Precigen (PGEN)
(Delayed Data from NSDQ)
$1.57 USD
-0.06 (-3.68%)
Updated Jun 18, 2024 03:59 PM ET
After-Market: $1.57 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PGEN 1.57 -0.06(-3.68%)
Will PGEN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PGEN
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
PGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
Other News for PGEN
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
6 Analysts Assess Precigen: What You Need To Know
Precigen stock rallies 17% on data for PRGN-2012 gene therapy
H.C. Wainwright Keeps Their Buy Rating on Precigen (PGEN)